anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The 2019 coronavirus disease (COVID-19), triggered by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), has seen numerous individuals undergo and recover from it, drawing extensive attention to their health conditions. Extensive studies indicate that even after surpassing the acute phase of infection, patients continue to experience persistent symptoms such as fatigue, pain, depression, weakening, and anosmia. COVID-19 appears not to have concluded but rather to persist long-term in certain individuals, termed as "long COVID." This represents a heterogeneous ailment involving multiple organ systems, with a perceived complex and still elusive pathogenesis. Among patients with long COVID, observations reveal immune dysregulation, coagulation impairments, and microbial dysbiosis, considered potential mechanisms explaining sustained adverse outcomes post COVID-19. Based on the multifactorial nature, varied symptoms, and heterogeneity of long COVID, we have summarized several categories of current therapeutic approaches. Furthermore, the symptoms of long COVID resemble those of other viral illnesses, suggesting that existing knowledge may offer novel insights into long-term COVID implications. Here, we provide an overview of existing literature associated with long COVID and summarize potential mechanisms, treatment modalities, and other analogous conditions. Lastly, we underscore the inadequacies in long COVID treatment approaches and emphasize the significance of conducting further research and clinical trials.
FIELD: medicine. SUBSTANCE: method involves applying receptor-binding vasoactive intestinal peptide bound in covalent way to chelating component of technetium or rhenium. Derivatives of receptor-binding vasoactive intestinal peptides marked with technetium-99m are used as scintigraphic reflecting agents. Derivatives of receptor-binding vasoactive intestinal peptides and vasoactive intestinal peptide analogs marked with cytotoxic radioactive isotopes like rhenium-186 ( 188 Re) or rhenium-188 ( 188 Re) are used as radiotherapy agents. EFFECT: improve production method; wide range of radiological and therapeutical application fields. 11 cl, 5 tbl
The intervention group will carry out a 12-week exercise-based intervention delivered via the VirtualRehab platform. The exercise-games have been designed from conventional physiotherapy exercises for stroke rehabilitation. A personalised training programme will be created for individual participants by a qualified physiotherapist member of the research team. Each participant will be asked to undertake their set exercise-based training programme for one hour a day, six days a week for 12 weeks.
The invention discloses the present invention provides a kind of Lonicera and Forsythia bagged instant preparation preparation method that reservation volatile oil content is stablized, include the following steps：A. following raw material are weighed by weight：0.8~1.6 part of honeysuckle, 0.8~16 part of Fructus Forsythiae, 0.5~0.9 part of peppermint, 0.3~0.6 part of schizonepeta, 0.5~0.9 part of great burdock achene, 0.5~0.9 part of campanulaceae, 0.5~0.8 part of Fermented Soybean, 0.5~0.9 part of reed root, 0.3~0.6 part of lophatherum gracile, 0.5~0.8 part of Radix Glycyrrhizae；B. raw material classification preliminary working；C. volatile oil is extracted；D. crushing, dispensing, mixing；E. it pelletizes, is dry；F. whole grain, total mixed.The present invention can be effectively retained the volatile oil in Lonicera and Forsythia bagged instant preparation in the case where sterilizing is thorough and ensures Product Safety, its product is made to have more preferable curative effect, ensure its validity, and production efficiency is high.
Diagnosed adenomatous low risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 1 to 4 non-advanced adenomas (\<10mm, without hairy component or high-grade dysplasia) or non-advanced serrated polyps (\<10mm, without dysplasia).
Real-world utility of Schedule II immediate release opioids depends on both efficacy and side effects. Few existing data sources systematically captured opioid-related side effects and their impact on patient outcomes and physician practice. This study is expected to lead to an in-depth understanding of patient and prescriber perceptions of both effectiveness and side effects associated with medications containing the most widely prescribed oral Schedule II immediate release opioid for pain management, oxycodone immediate release (OXYRX), alone (eg, Roxicodone®) or in combination (eg, Percocet®, Tylox®) in actual clinical practice. This is a prospective, multi-center, observational patient registry. Adult outpatients who have pain due to a non-cancerous condition meeting study eligibility will be enrolled. Prescribers will treat patients according to their usual practice. Prescribers will treat patients, meeting study eligibility, with OXYRX according to their usual practice.
The present invention discloses a pill for treating mastopathy, which is prepared from 15 to 25 wt% of common anemarrhena rhizome, 15 to 25 wt% of phellodendron bark, 12 to 20 wt% of putamen manidis, 12 to 20 wt% of cochinchina momordica seed, 12 to 20 wt% of nut grass, 10 to 15 wt% of bupleurum root and 10 to 15 wt% of liquorice. The common anemarrhena rhizome and the phellodendron bark are used as the main materials for nourishing yin, clearing away heat and regulating endocrine to balance. The putamen manidis and the cochinchina momordica seed are used as auxiliary materials for softening hard masses, eliminating swelling, expelling and detoxifying toxin, and promoting hyperplastic tissue absorption. The nut grass and the bupleurum root are used as the auxiliary materials for quickening qi, relieving stasis, soothing livers, clearing away heat and enhancing the rehabilitation of mammary glands. The liquorice is used for regulating the synergistic effect of the medicines, and thereby, the pill of the present invention can effectively treat mastitis and lobuli glandulae mammariae hyperplasy. The pill of the present invention has the advantages of little dosage, obvious effect, short course of treatment, excellent treatment effect and high healing rate, and furthermore, diseases do not recur after being healed. The pill has special effect on acute and chronic mastitis, lobuli glandulae mammariae hyperplasy and comedomastitis.
The present invention relates to a wolf oil pill for treating cough and asthma, which is a Chinese medicine preparation with the grease of a wild animal wolf as a main component. The wolf oil pill is mainly used for treating trachitis and asthma. Through the trial of exploratory research for a plurality of years, xanthium and honey are selected and matched to be made into a pill or a capsule. The wolf oil pill is a good special medicine with the best effect and the lowest expense relatively. The medicine is also a good inflammation relieving medicine and a blood reducing and dirt removing medicine. Through external application, the medicine can relieve inflammation and alleviate pain for various skin traumas and furuncles. Through oral administration, the medicine can be used for the reduction of blood fat in blood and the dust suction of lung surfaces. The present invention is a green medicine with good development and utilization value.
Patients will first be identified based on the inclusion criteria, then informed about the study and consented. Those who meet the exclusion criteria will be randomized to treatment or placebo. Enrolled participants will be randomized 2:1 to receive vitamin D (n=20) or placebo (n=10) for 6 months. All participants will be tested twice over two weeks to establish baseline values. Following baseline testing, the treatment group will receive 50,000 IU (standard replacement therapy) of oral cholecalciferol or placebo. The initial dose of cholecalciferol will be 50,000 IU weekly for 6 weeks. Vitamin D levels will then be measured. Participants who still have Vitamin D insufficiency ( 35 ng/ml) will remain on 50,000 IU of cholecalciferol for another 6 weeks, at which point Vitamin D levels will be measured again. Participants who reach 25-OH levels \> 35 ng/ml will have their dosing regimen lessened to 10,000 IU weekly (maintenance dose) for the remainder of the 6 months. Participants receiving placebo will start taking the placebo maintenance dose after the first 6 weeks. For safety monitoring, 25(OH) vitamin D3 levels will also be re-measured at monthly intervals and followed by an independent medical monitor. In patients who have serum vitamin D levels 60ng/ml, the frequency of administration will be reduced to once a month. The participants will receive supplementation for a total of 6 months. At this time, vitamin D levels will be reassessed and participants will undergo follow-up functional assessments, and cognitive and immune testing.
PURPOSE: A natural deodorant composition containing Rosa davurica PALL., bamboo leaves, and Chenopodium quinoa Willd. is provided to reduce body odor and to ensure high safety. CONSTITUTION: A deodorant composition contains extracts of Rosa davurica PALL., bamboo leaves, and Chenopodium quinoa Willd. as active ingredients. The extracts are prepared using purified water or ethanol. The ethanol extract is prepared by mixing 25g of plant samples and 500ml of 70% ethanol, stirring at 500 rpm for 3 hours, filtering the extract, and concentrating at a reduced pressure and 45 deg.C. [Reference numerals] (AA) Ammonium removal test result; (BB) Concentration(ppm); (CC) Elapsed time(hr)
BACKGROUND AND OBJECTIVES: The neuroprotectant nerinetide has shown promise in reducing infarct volumes in primate models of ischemia reperfusion. We hypothesized that early secondary infarct growth after endovascular therapy (EVT) (1) may be a suitable surrogate biomarker for testing neuroprotective compounds, (2) is feasible to assess in the acute setting using sequential MRI, and (3) can be modified by treatment with nerinetide.
METHODS: REPERFUSE-NA1 was a prospective, multisite MRI substudy of the randomized controlled trial ESCAPE-NA1 (ClinicalTrials.gov NCT02930018) that involved patients with acute disabling large vessel occlusive stroke undergoing EVT within 12 hours of onset who were randomized to receive intravenous nerinetide or placebo. Patients enrolled in REPERFUSE-NA1 underwent sequential MRI <5 hours post-EVT (day 1) and at 24 hours (day 2). The primary outcome was total diffusion-weighted MRI infarct growth early after EVT, defined as the lesion volume difference between day 2 and day 1. The secondary outcome was region-specific infarct growth in different brain tissue compartments. Statistical analyses were performed using the Mann-Whitney U test and multiple linear regression.
RESULTS: Sixty-seven of 71 patients included had MRI of sufficient quality. The median infarct volume post-EVT was 12.98 mL (IQR, 5.93-28.08) in the nerinetide group and 10.80 mL (IQR, 3.11-24.45) in the control group (p = 0.59). Patients receiving nerinetide showed a median early secondary infarct growth of 5.92 mL (IQR, 1.09-21.30) compared with 10.80 mL (interquartile range [IQR], 2.54-21.81) in patients with placebo (p = 0.30). Intravenous alteplase modified the effect of nerinetide on region-specific infarct growth in white matter and basal ganglia compartments. In patients with no alteplase, the infarct growth rate was reduced by 120% (standard error [SE], 60%) in the white matter (p = 0.03) and by 340% (SE, 140%) in the basal ganglia (p = 0.02) in the nerinetide group compared with placebo after adjusting for confounders.
DISCUSSION: This study highlights the potential of using MR imaging as a biomarker to estimate the effect of a neuroprotective agent in acute stroke treatment. Patients with acute large vessel occlusive stroke exhibited appreciable early infarct growth both in the gray matter and the white matter after undergoing EVT. Acknowledging relatively small overall infarct volumes in this study, treatment with nerinetide was associated with slightly reduced percentage infarct growth in the white matter and basal ganglia compared with placebo in patients not receiving intravenous alteplase and had no effect on the total early secondary infarct growth.
TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT02930018.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with acute large vessel ischemic stroke undergoing EVT, nerinetide did not significantly decrease early post-EVT infarct growth compared with placebo.
INTRODUCTION: Diarrheal disease is a global public health concern, particularly in low-income countries. In Ghana, widespread issues like inadequate sanitation, unsafe drinking water, malnutrition, and poor hygiene practices contribute to the high incidence of diarrhea. Climate change exacerbates these challenges by increasing the frequency and severity of conditions that spread diarrheal diseases. This study explores households' knowledge, understanding, and management practices for diarrhea in climate change-vulnerable coastal communities.
METHODS: The study is set in Ghana's central (Mumford, Opetekwei) and eastern (Anyako, Anyanui-Atiteti) coastlines. Using a cross-sectional study design, a structured questionnaire was administered to randomly sampled households (n = 419) to collect quantitative data. The study collected qualitative data from focus group discussions (n = 8), with groups separated into men and women, key informant interviews, and observations of food, water, and sanitation conditions across the studied communities.
RESULTS AND DISCUSSION: The study found significant variations between the studied communities and socio-demographic variables except for the respondents' gender. Multivariate regression analyses identified significant associations between socio-demographic variables (especially gender and educational status) and perceptions of diarrhea causes. The most used first management action against diarrhea is 'over-the-counter drugs', followed by home-made traditional remedies. Significant differences were observed in the usage of management practices across the studied communities. Trust, affordability, and availability were identified as the main factors influencing households' use of approved pharmaceutical drugs and traditional herbal remedies for managing behavior, with significant differences being observed across communities. The study recommends a multi-sectoral approach, including improved access to regularly flowing, safe water and sanitation facilities, education on preventing diarrhea, and adequate healthcare services. Community-based interventions such as promoting good hygiene practices at homes and community settings such as schools, lorry parks, funeral grounds, and recreational areas can also effectively reduce the burden of diarrhea.
AIM: The pathophysiological mechanisms of postoperative delirium (POD) are still unclear, and there is no reliable biomarker to distinguish between those with and without POD. Our aim was to discover DNAm markers associated with POD in blood collected from patients before and after gastrointestinal surgery.
METHOD: We collected blood samples from 16 patients including 7 POD patients at three timepoints; before surgery (pre), the first and third postoperative days (day1 and day3). We measured differences in DNA methylation between POD and control groups between pre and day1 as well as between pre and day3 using the Illumina EPIC array method. Besides, enrichment analysis with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes terms were also performed after excluding influence of common factors related to surgery and anesthesia.
RESULT: The results showed that pre and day1 comparisons showed that immune and inflammatory signals such as 'T-cell activation' were significantly different, consistent with our previous studies with non-Hispanic White subjects. In contrast, we found that these signals were not significant any more when pre was compared with day3.
CONCLUSION: These results provide strong evidence for the involvement of inflammatory and immune-related epigenetic signals in the pathogenesis of delirium, including POD, regardless of ethnic background. These findings also suggest that DNAm, which is involved in inflammation and immunity, is dynamically altered in patients with POD. In summary, the present results indicate that these signals may serve as a new diagnostic tool for POD.
Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
The present study tried to verify whether an intestinal agent and an antidiarrheal agent have an effect of suppressing the proliferation of food poisoning bacteria, whether the proliferation of food poisoning bacteria is controlled when lactic acid bacteria contained in the intestinal agent are separated and then co-cultured with the food poisoning bacteria, and whether, if the control ideally occurs, the supply of sugar and whey can increase the control efficiency. Twelve mice are divided into four groups with three mice, and one group is prepared for a control group, and the other three groups are set for groups of Ercefuryl, Lalacan, and a mixture of Ercefuryl and Lalacan. Appropriate amounts of the intestinal agent and the antidiarrheal agent are calculated referring to data of experiment ″A″, and then the drugs are mixed with 200 ml of distilled water. The weight change is observed for 2 weeks. The experiment was carried out for largely five items: analysis of major ingredients of the intestinal and antidiarrheal agent; change in the proliferation of food poisoning bacteria after addition of the intestinal and antidiarrheal agent; antagonistic actions of probiotic lactic acid bacteria and food poisoning bacteria; antibiotic effects of the intestinal and antidiarrheal agent on probiotic lactic acid bacteria and food poisoning bacteria; and effects of whey addition on the proliferation of probiotic lactic acid bacteria. The intestinal and antidiarrheal agent without lactic acid bacteria, Ercefuryl or Talstop, showed the possibility that E. collie or Salmonellae obtains resistance, but the probiotic agent, Duore or Lalacan, showed that the lactic acid bacteria reduced the number of harmful microorganisms through natural competition to maintain the intestinal balance, and such an effect can be increased by adding sugar and whey with appropriate concentrations. Therefore, it will be ideal to prescribe a probiotic agent together with whey containing an appropriate amount of sugar at the time of an intestinal agent proscription.
The invention belongs to the technical field of development of food-borne active peptides, and particularly relates to a tartary buckwheat peptide with DPP-IV inhibitory activity and application thereof. Two tartary buckwheat peptides with DPP-IV inhibition activity are obtained through tartary buckwheat protein preparation, enzymolysis, extraction, separation, purification and identification, and are RLSIRPP (SEQ ID NO. 2) and LHIVGPDK (SEQ ID NO. 3) respectively. The results of molecular docking analysis on the tartary buckwheat peptide and the DPP-IV enzyme show that the tartary buckwheat peptide and the amino acid residues of the DPP-IV enzyme have 11 hydrogen bonds, 6 hydrophobic interactions, 2 electrostatic bonds and 18 Van der Waals interactions; enzyme inhibition kinetics studies indicate that the inhibition of DPP-IV by tartary buckwheat peptide is a competitive and non-competitive mixed inhibition type. The DPP-IV tartary buckwheat inhibitory peptide can be used for developing health-care food and medicines for reducing blood sugar.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent for adverse effect symptoms of adrenal cortical steroid, safe and usable for a long period of time, capable of suppressing inhibitory actions immune function and inhibitory actions and inhibitory action on granulation tissue proliferation as adverse effects of adrenal cortical steroid, by including a lactic acid bacterium culture product. SOLUTION: This agent comprises a lactic acid bacterium competitive culture product as an active ingredient. Preferably a lactic acid bacterium containing at least one kind of Lactobacillus lactis and a streptococcus (e.g. B. bulgaricus A) in each group and a strain obtained by subjecting plural lactic acid bacterium groups different in the groups in each group to primary culture at 37 deg.C on the average for 120 hours, joining the culture products of the groups and subjecting the joined culture products to second culture is used as the lactic acid bacterium. An extract derived from a microbial cell solution obtained by grinding and extracting a metabolic product during the culture and a microbial cell is used as the active ingredient. An effective amount for treating an atopic patient is preferably 0.01-50 wt.% based on 1 g of a base.
The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
The 2015-2020 Dietary Guidelines advocate intake of lean proteins (such as chicken and fish) while limiting intake of saturated fat. Chicken contains similar protein to beef or pork but has less saturated fat. However, chicken, like other terrestrial meats, has little omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) and relatively little vitamin D. Vitamin D insufficiency is common in the US and globally, and has been linked to a number of adverse health outcomes. Vitamin D is ingested primarily from fortified dairy products, but recent animal studies have increased the D content of pork and beef, and the DHA content of chicken. Moreover, sunlight exposure alone can enhance the 25(OH)D content of chicken. Notably, supplemental 25(OH)D is more effective than vitamin D at improving vitamin D status in humans, but little is known about the bioavailability of 25(OH)D or DHA/EPA enhanced chicken (muscle).
A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells and/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21. Methods are also disclosed for inducing apoptosis of a B cell and for decreasing the number of B cells. A method is also described for producing a B cell hybridoma.